Debiopharm

✨Exciting times ahead in the field of AI and oncology! Altis Labs, one of our Innovation Fund investment portfolio companies, has been making waves with their innovative AI models. Their work was recently featured in STAT News.👇 Altis Labs' AI models have shown promising results in accelerating clinical development by providing a stronger predictor of overall survival - the gold standard measure of efficacy in oncology trials.👏 We're incredibly proud to support Altis Labs on their journey and look forward to seeing what they achieve next.🚀

💡Could targeted and potent ADCs dramatically change the future of cancer care? We’re exploring the impact of these emerging therapies with our new ”ADC Targeted Talks” series to discuss ADC development from different angles of our expertise. 🎬 Our CEO, Bertrand Ducrey is kicking off the series! 👇 We all want new hope for our loved ones fighting cancer. ADCs could revolutionize cancer treatment by enabling highly targeted delivery of potent, cytotoxic drugs directly to cancer cells, minimizing damage to healthy tissues 🎯. The future of ADCs lies in the identification and targeting of a broader range of cancer-specific antigens, along with the development of innovative drug linkers and payloads. We are happy to share learnings and ideas on how to best drive the creation of ADCs capable of addressing previously untreatable or resistant cancer types, offering a new arsenal for clinicians in the fight against cancer. ➡️Follow the video series for the next episodes with our Associate Principal Scientist, Lisa Ivanschitz, who will walk us through insights on CD37 targeted ADC therapy and with Léo Marx, Medicinal Chemist and Bioconjugates Manager, who will address the innovation drivers for the linker-payload construct.✨ About our ADC expertise : https://lnkd.in/ejVbFHmP #TargetedTherapy #AntibodyDrugConjugates #CancerResearch

✨Spotlight on artificial intelligence in cancer R&D! Our 3rd Digital Day at Debiopharm highlighted the transformative power of AI in clinical development. Last week we delved into how AI can accelerate drug discovery, streamline trials, and enable personalized treatments. We're still buzzing with ideas on how to harness this potential in our research processes.🔬🚀 These insights continue to fuel our quest for faster and more efficient innovation for patient lives.   👉 Curious to know - how is your organization leveraging AI? #AI #DrugDiscovery #Innovation #PersonalizedMedicine #PharmaceuticalResearch Angela Zubel, Frederico Braga, Daniel Truhn, Thomas Devenyns, Jean Colombel, Charlotte Bunne

ADCs are widely recognized as a game-changer in oncology, but how well do we understand the complexities of their development process and the challenges that come with it? 👇 Join us on March 25 to hear from industry leaders, including Léo Marx, our Medicinal Chemistry & Bioconjugation Manager, as they will explore the challenges and innovative solutions in scaling up ADC process development. ✨Learn about strategies to address manufacturing-scale risks and how AI and automation are transforming the field. Don't miss out on this opportunity to deepen your understanding of ADC process development. Free Registration here 👇https://lnkd.in/e-U6fsVs #AntibodyDrugConjugates #DrugDevelopment #LifeScience #Event #Online

📢Time for BIO-Europe Spring in Milan! Let’s talk about DDR Inhibitors, ADCs, Long-lasting formulations and your company’s new compounds at Bio-Europe Spring next week. ✨ 👇Our team is all set to connect with the vibrant life science ecosystem and share the latest advances on our pipeline products. 🔬 🤝 We believe in the power of partnership and are on the lookout for promising molecules to in-license. Let's explore potential collaborations together!   Feel free to reach out to our Search & Evaluation team Dr. Diana Pignalosa, Damián Carvajal and Alberto Diaz Jimenez, or Business Development team Anja Bitterwolf, Mayte Ares,, Ilona Kotala and Luke Piggott See you there! 👋 #BIOEuropeSpring #Biopharma #DrugDevelopment #Oncology

Debiopharm s'engage à aider la Ville de Lausanne dans son plan audacieux de transition écologique, pour un futur plus propre et durable. 🌍   La santé passe par la qualité de l’air que nous respirons, c’est dans cet esprit, que nous sommes fiers d'annoncer la mise à disposition de nos bornes de recharge pour véhicules électriques aux chauffeurs de taxis lausannois durant les nuits et week-ends, et ce à prix coûtant. 🚗 🔋   💡L'exposition à la pollution atmosphérique engendre plusieurs problèmes de santé, notamment les maladies cardiaques, les accidents vasculaires cérébraux, le cancer du poumon et l'asthme. Engagés dans la lutte contre le cancer et les maladies infectieuses, nous sommes également un acteur local impliqué dans la protection de notre environnement. 🌳   Cette initiative marque une étape concrète de notre soutien continu à la mobilité durable. Actuellement au nombre de cinq, d’ici fin 2026 notre offre de bornes de recharge devrait s’étendre à une trentaine de places.✨ 👇Plus d'info dans notre communiqué de presse https://lnkd.in/evi823Nt Ville de Lausanne #Lausanne #Durabilité #Environement #MobilitéDurable #Ecologie

👉 What do you see as the biggest opportunity for AI in clinical development? How can we leverage digital advancements to bring new cancer medicines for patients? ✨Just wrapped up an insightful 3rd edition of our Digital Day here at Debiopharm. We delved into the transformative power of AI in Clinical Development and were fortunate to have an exceptional line-up of speakers who shared their expertise and insights on various topics - from the reality and future of AI in medicine, virtual twin experiences in Healthcare, to its role in R&D and personalized oncology. A special thank you to our guest speakers Daniel Truhn, Thomas Devenyns, Jean Colombel, Charlotte Bunne for their enlightening presentations👏. And a shout-out to our new Seed Fund investment companies: HopeAI, Raidium, Risklick, StratifAI and ViewsML Technologies.   As we continue this digital transformation journey in clinical development with AI at the forefront - we'd love to hear your thoughts.   Looking forward to continuing these conversations! #AI #ClinicalDevelopment #DigitalTransformation #VirtualTwins #AIinMedicine

Tomorrow, we celebrate International Women's Day ✨- a day that honors the remarkable achievements of women globally and advocates for accelerating strides towards gender parity. 🌟 👇Today we shine the spotlight on our colleague Mayte Ares, LL.M. Her dedication to her role at Debiopharm involves establishing partnerships with biotech and pharma companies always keeping in mind the ultimate goal - bringing new innovative therapies to patients globally. She's part of a larger community of women whose contributions continue to push boundaries across various fields.   This special day is an opportunity to reflect on the progress made, call for change, and celebrate women who have played extraordinary roles in their communities and fields. At Debiopharm, we witness the strength, determination, and resilience of incredible women every day. From our colleagues driving innovation to our family members inspiring us with their courage and friends supporting us unconditionally - each one plays a unique role in shaping our world.   As we stand on the brink of International Women’s Day tomorrow let’s take a moment to appreciate all these amazing women in our lives!✨ #InternationalWomensDay #IWD2025 #Celebration

Would you like to gain a deeper understanding of the challenges and innovative solutions in scaling up ADC process development?👇 Don't miss this panel discussion on March 25, where top ADC experts, including our Medicinal Chemistry & Bioconjugation Manager, Léo Marx, will share insights and experiences. 💡 They'll delve into the strategies employed by leading developers to mitigate manufacturing-scale risks and discuss how artificial intelligence and automation are reshaping the process. We hope you can join! #AntibodyDrugConjugates #DrugDevelopment #Innovation #OnlineEvent

💡How do modern nuclear medicine techniques contribute to better outcomes in prostate cancer care? 👇Check out this recent article published in European Urology and learn about the mission and activities of the Co-IMPACT project, supported by Debiopharm! https://lnkd.in/eANZ6Mck  🔬🧑🔬In line with our efforts and advances in nuclear medicine and Radioligand Therapy (RLT) over the past 10 years, and as a sponsor of this Consortium, we are proud to support the work of these international multidisciplinary experts who join efforts to optimize and improve prostate cancer care. 🎯 Combining prostate-specific membrane antigen (PSMA) radiotracers with Positron Emission Tomography (PET) imaging and radiotherapy (RT) represents an integrated precision-based approach in cancer care as it leverages the strengths of both diagnostic imaging and therapeutic radiation. As such, both RLT and PSMA-PET-guided RT are components of a broader theranostic approach and constitute a significant advancement in cancer care, offering a more targeted and effective treatment option.  ➡️ Make sure to visit the Co-IMPACT project page https://lnkd.in/eE6DiH3u if you are interested in joining the registry or simply to know more about the work of the experts and sites involved. Mohamed Shelan Constantinos Zamboglou, MHBA #NuclearMedicine #Radiotherapy #ProstateCancer #Cancercare #Innovation